|
Fred Hutchinson Cancer Research Center University of Washington
Medicine Qualifications: |
Dr. Hans-Peter Kiem received his M.D. and Dr. med. degrees from the University of Ulm. After working with Drs. Frickhofen and Heimpel at the University of Ulm he joined Dr. Karl Blume’s research group at Stanford University as a research fellow to study molecular abnormalities in patients with lymphoma and minimal residual disease. After a 2-year fellowship at Stanford he completed a residency in Internal Medicine at Vanderbilt University and in 1992 joined the Fred Hutchinson Cancer Research Center to complete a fellowship in Oncology.
Dr. Kiem’s main research interest has been stem cell biology and transplantation. He has more than 20 years of experience with hematopoietic cell transplantation and more than 15 years of experience with gene transfer and gene therapy studies. Hematopoietic stem cells (HSCs) are attractive targets for gene therapy because of their ability to permanently reconstitute the hematopoietic and immune systems after transplant. Many different congenital and acquired diseases could be treated by introducing new genes into stem cells and several diseases have now been successfully treated by HSC gene therapy.
Dr. Kiem’s recent research areas include the following:
• HSC biology
• HSC gene therapy for genetic and infectious diseases and cancer
• Dr. Kiem’s lab has two active clinical HSC gene therapy studies for patients
with Fanconi anemia and patients with glioblastoma
• HSC expansion and cord blood expansion
• Gene targeting using different types of nucleases
• Induced pluripotent stem cells (iPSCS) and iPSC-derived HSCs
• Gene therapy for HIV/AIDS